TSX · Biotechnology · CAD
Medicenna Therapeutics Corp. (MDNA.TO) Stock Analysis
Medicenna Therapeutics Corp. (MDNA.TO) is a Biotechnology stock listed on TSX and quoted in Canadian Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
MDNA.TO Key Statistics
As of Oct 21, 2026Trading
- Open
- CA$0.39
- Previous Close
- CA$0.39
- Day's Range
- 0.39–0.43
- 52-Week Range
- 0.34–1.97
- Volume
- 89.29K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 2.10
Valuation
- Market Cap
- CA$37.84M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.22
Financials (FY)
- Revenue (FY)
- CA$0.00
- Net Income (FY)
- −CA$18.41M
- Shares Outstanding
- 92.30M
- 1-Year Return
- −56.38%
Dividend and dates
- Earnings Date
- November 12, 2026estimated
- Avg Volume
- 45.30K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, MDNA.TO closed at CA$0.41, −56.38% over 1 year.
Medicenna Therapeutics Corp. (MDNA.TO) has a market capitalization of CA$37.84M.
In fiscal 2025, MDNA.TO reported revenue of CA$0.00.
MDNA.TO Stock Return by Calendar Year
Medicenna Therapeutics Corp. (MDNA.TO) return since Mar 2017: what CA$10,000 became
- 1 year
- CA$10,000 CA$4,362
- −56.38%
- 5 years
- CA$10,000 CA$1,302
- −86.98%
- Since Mar 2017
- CA$10,000 CA$1,519
- −84.81%
If you had invested CA$10,000 in Medicenna Therapeutics Corp. (MDNA.TO) at the close on March 8, 2017, the earliest close on record here, it would have been worth CA$1,519 at the close on October 21, 2026: −84.81% in total, −17.79% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −55.43% |
| 2025 | −44.24% |
| 2024 | +292.86% |
| 2023 | −34.38% |
| 2022 | −69.52% |
| 2021 | −64.71% |
| 2020 | +75.00% |
| 2019 | +385.71% |
| 2018 | −65.00% |
| 2017 (partial year) | −25.93% |
As of October 21, 2026.
MDNA.TO Revenue and Earnings by Fiscal Year
FY ends March| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | CA$0.00 | −CA$18.41M | — |
| 2024 | CA$0.00 | −CA$11.81M | — |
| 2023 | CA$0.00 | −CA$25.47M | — |
| 2022 | CA$0.00 | −CA$10.05M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | CA$0.00 | — | −CA$22.42M | −CA$18.41M | — |
| 2024 | CA$0.00 | — | −CA$20.41M | −CA$11.81M | — |
| 2023 | CA$0.00 | — | −CA$18.67M | −CA$25.47M | — |
| 2022 | CA$0.00 | — | −CA$16.30M | −CA$10.05M | — |
Annual figures as reported, in the company's reporting currency. As of March 31, 2026.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B